ICPT - Intercept Pharmaceuticals Inc (Healthcare: Biotechnology) Projected Earnings Date: 2024-06-03    (Delayed quote data   )
Last
 		 Change
 ⇓ 0.00   (%)		 Volume
  0
Open
 		 High
 		 Low
 
8EMA (Daily)
 0.00		 40EMA (Daily)
 		 50EMA (Daily)
 		 STO (Daily)
 		 MACD Hist (Daily)
 
8EMA (Weekly)
 17.459		 40EMA (Weekly)
 14.75		 50EMA (Weekly)
 14.85		 STO (Weekly)
 97.436		 MACD Hist (Weekly)
 1.727
Company Profile
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
optionchance optionchance
⇒ Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com